DIRS.INFO The most relevant business & tech news

☆ Microsoft picks company veteran Pavan Davuluri to lead Windows and Surface
▼ + stars: | 2024-03-26 | by ( Jordan Novet | ) www.cnbc.com time to read: +3 min

Microsoft said Monday it has selected company veteran Pavan Davuluri to lead its Windows operating system and Surface devices teams. Davuluri's promotion comes a week after Microsoft said it was hiring former DeepMind co-founder Mustafa Suleyman as the head of a new organization called Microsoft AI. The Windows team will continue to work closely with the Microsoft AI team on AI, silicon, and experiences.The Web Experiences team will report into Mustafa in the new Microsoft AI organization. Mike Davidson continues to lead Design and will work with Pavan and team on how to realign Windows design. They will join the Microsoft AI leadership team along with Jordi, Mike, and Rukmini, all reporting to Mustafa.We are excited for this team to help Microsoft AI achieve its bold ambition to build world-class consumer AI products.

Persons: Pavan Davuluri, Panos Panay, DeepMind, Mustafa Suleyman, Mikhail Parakhin, Parakhin, Kevin Scott, Rajesh Jha, Davuluri, Read, Satya, Shilpa Ranganathan, Jeff Johnson, Mustafa, Jordi Ribas, Andrey Proskurin, Fatima Kardar, Nick Lee, Rukmini Iyer, Paul Viola, Weiqing, Mike Davidson, Pavan, Ali Akgun, Kya Sainsbury, Carter, Qi Zhang, Rajesh Sundaram's, Jordi, Mike, Rukmini Organizations: Microsoft, Windows, Bing, WWE

☆ Media literacy is more than spotting fake news. How one librarian gives teens the tools to decide what to trust
▼ + stars: | 2024-01-21 | by ( Alisha Ebrahimji | ) edition.cnn.com time to read: +11 min

With lots of kids now getting their news from social media – where disinformation and content created by artificial intelligence run rampant – 18 states have some form of K-12 media literacy education on the books, according to Media Literacy Now. Of those, four – Delaware, Texas, New Jersey and, starting this year, California – mandate media literacy, with lesson standards now being crafted state by state. “But we haven’t really taught people how to use them ethically, efficiently and responsibly.”To do that, a media literacy lesson might include analyzing which emotions the wording of a mass media headline evoke. And California starting this year requires media literacy instruction to be integrated into K-12 mathematics, science and history-social science curriculums when they’re revised, according to the bill. It’s why Manganello has spent nearly two decades perfecting how she teaches media literacy.

Persons: Lisa Manganello, ” Manganello, ”, Olga Polites, seatbelts, “, ” Polites, Manganello, Jeff Johnson’s, Harrison Pekosz, Harrison, Urja Kandale, they’re, It’s, “ Young, aren’t, “ We’ve, ” Urja, Michelle Ciulla Lipkin, “ We’re, “ ‘, Elisabeth Yucis, Johnson Organizations: Brunswick , New Jersey CNN, South Brunswick High School, Smart, “ Media, CNN, ”, Literacy, Media Literacy, Social, Pew Research, Stanford University, “, Stanford, South Brunswick High, National Association for Media Literacy, Department, Professional, New Jersey Education Association Locations: Brunswick , New Jersey, Jersey, United States, Delaware, Texas , New Jersey, California, Olga Polites , New Jersey, TikTok, New Jersey, South Brunswick

☆ Medical device stocks rise in relief after Wegovy heart benefits data
▼ + stars: | 2023-11-13 | by ( ) www.reuters.com time to read: +2 min

A 0.25 mg injection pen of Novo Nordisk's weight-loss drug Wegovy is shown in this photo illustration in Oslo, Norway, September 1, 2023. To be sure, the full results presented on Saturday at a major medical meeting gave analysts even more confidence in the heart protective benefits of the hugely popular drug. That lifted shares of Penumbra (PEN.N), which makes devices used in surgeries for stroke patients, 13% in morning trading. Its shares have tumbled about 28% as of last close since Novo in August said Wegovy had also shown a clear cardiovascular benefit. "The full detailed results ... do not shift our outlook that MedTech device stocks appear broadly oversold," said Leerink analyst Mike Kratky.

Persons: Victoria Klesty, Wegovy, Baird, Jeff Johnson, Eli Lilly's, Mike Kratky, Leroy Leo, Medha Singh, Sriraj Organizations: REUTERS, Novo, Devices, Abbott Laboratories, Thomson Locations: Oslo, Norway, Victoria, MedTech, Penumbra, Novo, Friday's, Bengaluru

☆ Food retailers and producers are getting slammed as GLP-1 drugs like Ozempic raise growing alarms about demand
▼ + stars: | 2023-10-06 | by ( Matthew Fox | ) www.businessinsider.com time to read: +3 min

The rise of GLP-1 drugs is driving consumer-staple stocks lower as patients eat less food. Walmart's US CEO said he'd already seen patients using GLP-1 drugs buy less food at the retailer. AdvertisementAdvertisementConsumer-staple stocks have been slammed this week as investors try to size up the negative impact GLP-1 drugs such as Ozempic, Wegovy, and Mounjaro could have on food companies. And through its pharmacy unit, the company can use anonymized data to analyze the spending habits of its customers that are taking GLP-1 drugs. AdvertisementAdvertisementIn a Friday note, Bank of America estimated that GLP-1 drugs could quell addictive behaviors among consumers, which could lead to an overall decline in consumption of snacks and beverages.

Persons: he'd, —, McDonald's, John Furner, Jeff Johnson, Baird, Morgan Stanley Organizations: PepsiCo, Coca, Cola, Walmart, Costco, Service, Bloomberg, Bank of America Locations: GLP

☆ The disruptive effect of weight loss drugs like Ozempic could have surprising impacts on the stock market. Here are potential winners and losers.
▼ + stars: | 2023-09-24 | by ( Matthew Fox | ) www.businessinsider.com time to read: +7 min

The potential ripple effects of GLP-1 weight loss drugs like Ozempic and Wegovy are far-reaching. These are the stock market's potential winners and losers of the fast-growing weight loss drugs. By contrast, typical weight loss without GLP-1 drugs is mostly driven by a reduction in fat, not muscle. AdvertisementAdvertisementFast-food chains and junk-food companiesMorgan Stanley surveyed 300 patients taking GLP-1 drugs and found that calorie intake dropped 20%-30% on a daily basis. AdvertisementAdvertisementBeer and tobacco companiesAnecdotes from patients taking GLP-1 drugs indicate that the drug helps curb certain addictive behaviors like smoking cigarettes or drinking alcohol.

Persons: Eli Lilly, Catalent, Fisher, McKesson, Baird, Jeff Johnson, Johnson, Morgan Stanley, Kreme, Morgan Stanley's, Phillip Morris Organizations: Service, Street, Novo Nordisk, JPMorgan, Nordisk, Bloomberg, Fitness, Nike, Inspire, Tandem Diabetes Care, KFC, Yum Brands, Anheuser, Busch, Molson Coors Locations: Wall, Silicon, GLP

☆ Microsoft product chief Panos Panay is leaving the company
▼ + stars: | 2023-09-18 | by ( Jordan Novet | ) www.cnbc.com time to read: +5 min

Panos Panay, Microsoft's chief product officer, talks about Windows 11 at the Windows 11 launch event that was streamed live on June 24, 2021. Microsoft's product chief, Panos Panay, will leave the software and hardware maker, executive vice president Rajesh Jha told employees on Monday. The shakeup represents a changing of the guard after more than a decade of sales of Microsoft's Surface PCs, which Panay has presented to consumers at company events. Team,After nearly 20 years at the company, Panos Panay has decided to leave Microsoft. Best,RajeshWATCH: The Microsoft Surface Go is a good computer, but a very bad tablet

Persons: Panos Panay, Panos, Rajesh Jha, Yusuf Mehdi, Satya Nadella, Mehdi, Charles Simonyi, Jha, I've, I'm, Pavan Davuluri, Brett Ostrum, Nino Storniolo, Linda Averett, Ken Pan, Ralf Groene, Aidan Marcuss, Carlos Picoto, Stevie Bathiche, Robin Seiler, Ruben Caballero, Anuj, Shilpa Ranganathan, Jeff Johnson, Ali Akgun, Mikhail Parakhin, Terri Chudzik, Erin Kolb, Mike Davidson, Let's, Rajesh Organizations: Windows, Microsoft Locations: Panos Panay, Panay, New York

☆ Medical device maker Zimmer Biomet lifts profit forecast as surgeries rebound
▼ + stars: | 2023-08-01 | by ( ) www.reuters.com time to read: +1 min

Aug 1 (Reuters) - Zimmer Biomet Holdings Inc (ZBH.N) on Tuesday raised its full-year profit forecast, anticipating demand to hold up for its medical devices following a rebound in knee and hip replacement procedures. Abbott Laboratories (ABT.N) attributed its strong quarter to hospitals addressing bottlenecks from the pandemic while Johnson & Johnson (JNJ.N) said it expected to top profit estimates with surgeries bouncing back. The company now expects full-year profit of $7.47 to $7.57 per share, compared with its previous forecast of $7.40 to $7.50. The Indiana-based company's second-quarter revenue rose nearly 5% to $1.87 billion, beating analysts' estimates of $1.83 billion. Zimmer also expects reported revenue to grow between 6.5% and 7% this year, compared to its prior forecast of between 5% and 6%.

Persons: Zimmer, Johnson, Jeff Johnson, Mariam Sunny, Sriraj Organizations: Zimmer Biomet Holdings, Abbott Laboratories, Baird Equity, Thomson Locations: Indiana, Bengaluru

☆ Investing in muni bonds: Separatley managed accounts surge
▼ + stars: | 2023-07-21 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailInvesting in muni bonds: Separatley managed accounts surgeJeff Johnson, Appleton Partners SVP, joins 'The Exchange' to discuss the benefits of separately managed accounts over mutual funds, the control, customization, and transparency afforded to clients using SMAs, and how new technology has helped make SMAs more affordable.

Persons: Separatley, Jeff Johnson Organizations: Appleton Partners Locations: muni

☆ Munis are set up to have a good year in 2023, says Appleton's Jeff Johnson
▼ + stars: | 2022-12-20 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailMunis are set up to have a good year in 2023, says Appleton's Jeff JohnsonJeff Johnson, Appleton Partners senior vice president, joins 'The Exchange' to discuss the outlook for municipal bonds in 2023.

☆ This little-known contact lenses stock can surge 20% from here, Baird says
▼ + stars: | 2022-11-30 | by ( Sarah Min | ) www.cnbc.com time to read: +1 min

There's big upside in shares of Cooper Companies , a company known for manufacturing contact lenses, according to Baird. "While we expect COO to miss FQ4 and guide FY'23 EPS below Street, we've been encouraged by recent still-healthy contact lens end-market checks and expectations pricing tailwinds could grow for CVI next year," Johnson wrote in a Wednesday note. The analyst's $370 price target, raised from $345, represents roughly 20% upside from Tuesday's closing price of $307.44. However, the analyst said that his checks into contact lens end markets have improved in recent months. What's more, he expects that price increases for contact lenses that proved to be sticky this year, will continue in 2023.

Search resuls for: "Jeff Johnson"

10 mentions found